Literature DB >> 9822548

Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.

G Subramanian1, M G Paterlini, D L Larson, P S Portoghese, D M Ferguson.   

Abstract

The three-dimensional structure, dynamics, and binding modes of representative kappa-opioid agonists of the arylacetamide class (U50, 488; U69,593; U62,066; CI-977; ICI199,441; ICI197,067; BRL52,537; and BRL52,656) have been investigated using molecular modeling techniques. Systematic exploration of the conformational space of the ligand combined with molecular dynamics (MD) simulations in water revealed consistent conformational preferences for all the kappa-agonists in this series. The results were further compared with available X-ray and 1D- and 2D-NMR data to identify potential "lead" conformers for molecular docking. Ligand binding modes were initially determined using automated docking of two of the ligands (U50,488 and BRL52,537) to the kappa-opioid receptor. Extrapolation of the predicted binding mode to other members in this ligand series revealed similar docking preferences, with each ligand docked along the receptor helical axis. The binding modes were further refined using MD simulations of the receptor-ligand complexes. The results show a that salt bridge is formed between the amino proton of the ligands and the carboxylate group of Asp138 in TM3. This interaction most likely serves as a key anchoring point for the agonist association. Additional ligand contacts were noted with kappa-specific residues Ile294, Leu295, and Ala298, which may, in part, explain the kappa-selectivity in this series. In comparing the arylacetamides with opiate-based ligands, no evidence was found to link these classes through a common binding motif (except for the ion pair). The binding site model was also applied to explain the enantiomeric preference of U50,488 and to provide insight to the mu/kappa-selectivity of representative ligands in this series. Overall, the results provide a structure-based rationale for ligand recognition that is consistent both with site-directed mutagenesis experiments and structure-function relationship data.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9822548     DOI: 10.1021/jm9803166

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity.

Authors:  M Germana Paterlini
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

Review 2.  Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Authors:  Irina D Pogozheva; Magdalena J Przydzial; Henry I Mosberg
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 3.  Molecular recognition of opioid receptor ligands.

Authors:  Brian E Kane; Bengt Svensson; David M Ferguson
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

Review 4.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

Review 5.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

6.  The atomistic level structure for the activated human κ-opioid receptor bound to the full Gi protein and the MP1104 agonist.

Authors:  Amirhossein Mafi; Soo-Kyung Kim; William A Goddard
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-03       Impact factor: 11.205

7.  Insight into the binding model of new antagonists of kappa receptor using docking and molecular dynamics simulation.

Authors:  Shiyuan Hu; Haijing Yu; Yongjuan Liu; Tian Xue; Huabei Zhang
Journal:  J Mol Model       Date:  2013-04-20       Impact factor: 1.810

8.  Insights into subtype selectivity of opioid agonists by ligand-based and structure-based methods.

Authors:  Jianxin Cheng; Guixia Liu; Jing Zhang; Zhejun Xu; Yun Tang
Journal:  J Mol Model       Date:  2010-05-25       Impact factor: 1.810

9.  Structure of the human κ-opioid receptor in complex with JDTic.

Authors:  Huixian Wu; Daniel Wacker; Mauro Mileni; Vsevolod Katritch; Gye Won Han; Eyal Vardy; Wei Liu; Aaron A Thompson; Xi-Ping Huang; F Ivy Carroll; S Wayne Mascarella; Richard B Westkaemper; Philip D Mosier; Bryan L Roth; Vadim Cherezov; Raymond C Stevens
Journal:  Nature       Date:  2012-03-21       Impact factor: 49.962

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.